Printer Friendly

MAGAININ RECEIVES PATENT FOR ANTI-INFECTIVE COMPOUND COMPANY'S SIXTH HOST DEFENSE RELATED PATENT

 PLYMOUTH MEETING, Pa., April 30 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced the issuance of a patent for the composition and use of the first antibiotic isolated from the airway of an animal. Scientists believe that this tracheal antimicrobial peptide might play a key role in defending the respiratory tract from infectious diseases. In laboratory tests, it has demonstrated a broad spectrum or antibacterial and antifungal activity.
 "Magainin and its collaborators have filed over 40 host defense related patents, of which six have now issued. The issuance of the tracheal antimicrobial peptide patent reinforces Magainin's leadership position in the discovery of new anti-infectives from the host defense system of animals, " said Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals. Mr. Moorin further commented that the need for new anti-infectives has become more apparent as bacterial pathogens become increasingly resistant to current antibiotic therapies.
 The patent was issued to Dr. Michael Zasloff, currently executive vice president of Magainin Pharmaceuticals and president of the Magainin Research Institute, and his collaborators. The company has an exclusive worldwide patent license agreement for the rights to the patent.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti-infectives and anti-cancer products based upon compounds isolated from the host defense systems of animals.
 -0- 4/30/93
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals Inc., 215-941-4020; or Fern Lazar or Kate de Santis of Dew Rogerson, 212-688-6840, for Magainin Pharmaceuticals./
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:

TS-LR -- NY013 -- 3050 04/30/93 08:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:261
Previous Article:SAFECARD SERVICES ENDS LEGAL PROCEEDINGS AGAINST THE IRS AND ITS AGENTS
Next Article:DNAP PRODUCT SALES DOUBLE OVER PREVIOUS YEAR; CHERRY TOMATO PRODUCT LINE LAUNCHED INTO SAN DIEGO AND PHILADELPHIA MARKETS
Topics:


Related Articles
MAGAININ PHARMACEUTICALS FISCAL 1992 FINANCIAL RESULTS IN LINE WITH EXPECTATIONS
MAGAININ PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF 3,500,000 SHARES
OVER-ALLOTMENT OPTION EXERCISED IN MAGAININ PUBLIC OFFERING
MAGAININ APPOINTS CHIEF OPERATING OFFICER
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
Magainin Announces Cytolex Collaboration with SmithKline Beecham in North America
Magainin and University of Pennsylvania Report in Cell on Key Peptide In Cystic Fibrosis-Associated Lung Infection
Diversa Signs Agreement With GlaxoSmithKline to Advance Development of a Novel Anti-Infective Compound.
CEL-SCI Receives U.S. Patent For CEL-1000 Anti-Infective Drug.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters